30 July 2021
LIMITLESS EARTH PLC
("Limitless" or the "Company")
Final Results for
the year to 31 January 2021
The Company announces its final results for the year to
31 January 2021.
The Annual Report and Accounts for the year ended 31 January 2021 will shortly be posted to
shareholders and uploaded to the Company’s website,
www.limitlessearthplc.com.
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
For further information, please contact:
Limitless Earth
plc
+44 (0) 7780 700 091
Guido Contesso
www.limitlessearthplc.com
Cairn Financial Advisers
LLP
+44 (0) 20 7213 0880
Nominated
Adviser
www.cairnfin.com
Jo Turner/Sandy Jamieson
Peterhouse Corporate Finance
Limited
+44 (0) 20 7469 0930
Broker
www.pcorpfin.com
Duncan Vasey / Lucy Williams / Eran Zucker
Chairman’s Statement
The Company has continued to focus on investing in opportunities
highlighted by demographic trends. This has governed the selection
of our existing investments including cleantech (Saxa Gres), life
sciences (Chronix) and technology (V-Nova and Exogenesis).
The board is aware of the importance of making the right
investment in the right sector at the right time and has and will
only consider investing in opportunities that fit into its
investing policy. In recent years, the board has elected to
make follow-on investments into its investee companies rather than
source new investment opportunities, but it continues to review and
consider investment opportunities and will only invest in the best
of those reviewed.
The Company has cash and cash equivalents at the reporting date
of £157,310, and post yearend, the company entered into an
agreement to dispose part of the investment in the Saxa Gress bonds
to provide ongoing working capital. The board considers it has
sufficient cash for its operations for the financial year ahead and
the board will look to exit investments when the conditions are
supportive.
The Company’s investing policy is to principally invest in
sectors where changing demographic factors are important drivers of
growth and these investments may be in either quoted or unquoted
securities made directly or indirectly in partnerships or joint
ventures or into individual assets and can be at any stage of
development. To date the board has made direct investments in
opportunities where other investors may or may not
participate. Given the unprecedented changes in the last year
and market volatility brought about by significant factors such as
Brexit and the COVID pandemic, the board considers it likely that
it will focus on co-investment opportunities from management's
extensive, high level contacts in the areas of family wealth and
asset wealth management. It is expected this will assist in
providing greater liquidity to exit and access to follow-on funding
for the investee company in the event it is required, helping the
board better manage its exposure to risk and divestment.
The investments made to date are in the form of equity to
convertible loans and all investments are valued £1,874,083 at fair
value. To determine the fair value of each investment, the
directors have reviewed all the information received from each
investee company and also from publicly available information on
the internet. For V- Nova International Ltd, there was a placing by
the investment in October 2020 that
uplifted the fair value of that investment by £100,000.
The information available on the other three investments were all
positive, however insufficient information to demonstrate that the
fair value is anything other than cost as a result of a lack of
other inputs or evidence to suggest an uplift or impairment of the
value.
The investments are:
Saxa Gres S.p.A, a turn-around circular economy
company which specialises in an innovative tile production process,
has been extremely successful in expanding its operations by
competitor acquisitions and this has enabled it to satisfy the
increasing demands for its products while attracting valuable
funding from relevant institutional investors.
Saxa’s founders, management and professionals have demonstrated
outstanding achievements in terms of the development of its
operations, sales, product expansion and integration of its
acquisitions and during the reporting period, A2A S.p.A, a €4
billion listed company took a holding in this investment of 27.7%
and as a relevant industrial partner, they could help to
expand and solidify Saxa Gres’ successful business model.
Saxa’s impact investments side; it builds synthetic stone
using industrial waste fulfilling a number of green economy
requirements and having significant environmental benefits.
V-Nova International Ltd. is a London-headquartered technology company
providing next-generation compression solutions that address the
ever-growing media processing and delivery challenges. V-Nova, as
an IP software company, has developed an innovative video and
imaging compression technology, with a valid proof of revenues and
concept also in relevant emerging markets countries.
V-Nova’s LCEVC (Low Complexity Enhancement Video Coding) is the
industry’s first highly optimised implementation of MPEG-5 Part 2
LCEVC, the codec-agnostic ISO/IEC enhancement standard capable of
providing higher quality at up to 40% lower bitrates than codecs
used natively. Its unique low-complexity design can allow for
immediately accelerated encoding by up to 4 times compared to other
commonly used codecs via a simple software upgrade, producing
significant transcoding cost efficiencies.
V-Nova’s management have helped ensure that the company’s
technology is becoming an integrated world standard. The Company is
optimistic that V-Nova may be at a stage of development where it
will be able to exploit its years of hard work and, importantly,
recoup the investment in it as it progresses towards reaching
profitability and expanding V-Nova’s patented capabilities in as
many verticals as possible.
V-Nova’s impact investment angle: significantly more
efficient data processing leads to reduced power consumptions
offering a valuable reduction of carbon emissions per hour of
video, providing relevant environmental sustainability benefits to
video workflows (source
https://www.broadbandtvnews.com/2021/05/24/v-nova-lcevc-announces-licensing-terms/
)
Due to the exponential video consumption growth, it materially
increase the energy savings in the near future like direct server
electricity consumption, it assists in reducing hardware
replacement rates or providing greater reach to using with older
technology and it drives indirect savings in areas including:
manufacturing costs, cooling, content transmission (CDN), storage
and caching and end user decoding.
Chronix Biomedical, inc. is a privately-owned biotech
company founded in 1997 which specialises in simple blood tests
(liquid biopsies) for real-time monitoring of the effectiveness of
cancer drugs, including immunotherapies, and rejection of
transplanted organs. The cancer test is based on a patented
technology whereby Chronix can identify gains and losses in cell
free DNA that allow them to determine if a cancer therapy is
working. The transplant test allows Chronix Company to determine if
the organ that is transplanted is being accepted or rejected, and
thereby allows the physician to alter the immunosuppressive drug
regimen given to the patient.
In June 2018, Chronix signed its
first commercial agreement with a large EU-based lab group, which
already processes more than 150,000 laboratory samples daily,
providing an exclusive licence for Germany, Austria, Switzerland and Belgium. The contract is for 15 years and
Independent research analysts have estimated the net present value
of the licensing payments to Chronix over the life of the agreement
to be approximately $92 million.
In April 2021 Oncocyte, a listed
Nasdaq Company, bought Chronix Biomedical allowing them to use
their network to distribute Chonix’s products. As part of the terms
of the acquisition, Chronix’s shareholders received rights to
future revenues on products sold.
Chronix’s impact investment angle: Chronix’s tests
provide the opportunity for patients and healthcare provides to
avoid billions of pounds of diagnostic surgery costs, for patients
to avoid invasive surgery, healthcare provides to reduce demand on
resources. Chronix’s products provide for cost effecting,
surgery free treatment monitoring which could lead to more
effective care and treatments, saving money and lives.
Exogenesis Corporation Headquartered Massachusetts, USA,
Exogenesis is a private, venture-capital-backed company that has
developed and is commercialising a proprietary technology to modify
and control surfaces without applying a coating or creating
sub-surface damage. Exogenesis is commercialising a platform
technology, NanoAccel™, using Accelerated Neutral Atom Beam (ANAB)
and Gas Cluster Ion Beam (GCIB) technologies that modify and
control surfaces of materials at a nanoscale level. The company's
proprietary technologies are used for surface modification and
control in a broad range of biomedical, optical and semiconductor
applications.
Although the Board are optimistic and recognise Exogenesis’
technological achievements, the investment is pre revenue and we
look forward to further news
Exogenesis’ impact investment angle: its technology can
modify materials in order to alter their behaviour or effectiveness
or change their chemical and/or physical properties to replicate
other, more expensive materials.
It is the intention of the board to seek to exit the current
investments which have performed well, when conditions provide for
a successful exit, in order to provide funds for
reinvestment. The board looks forward to updating
shareholders with any progress in the year ahead.
Guido Contesso
Chief Executive Officer
Income Statement and Statement of Comprehensive Income
for the year ended 31 January
2021
|
|
|
|
|
|
Year
ended
31 January |
Year
ended
31 January |
|
|
2021 |
2020 |
Continuing
operations |
|
£ |
£ |
|
|
|
|
Investment income |
|
27,583 |
37,797 |
Total
income |
|
27,583 |
37,797 |
Administrative
expenses |
|
(78,076) |
(216,332) |
Operating loss and
Loss before taxation |
|
(50,493) |
(178,535) |
|
|
|
|
Taxation |
|
- |
- |
Loss for the
year |
|
(50,493) |
(178,535) |
Total comprehensive
loss for the year |
|
(50,493) |
(178,535) |
|
|
|
|
Earnings per
share: |
|
|
|
Basic and diluted
earnings per share |
|
(0.00077) |
(0.0027) |
|
|
|
|
There are no items of other comprehensive income.
Statement of Financial Position
As at 31 January 2021
|
|
2021 |
2020 |
|
|
£ |
£ |
|
|
|
|
Non-current
assets |
|
|
|
Financial asset
investments at fair value through profit and loss |
|
1,874,083 |
1,763,386 |
Non-current
assets |
|
1,874,083 |
1,763,386 |
|
|
|
|
Current
assets |
|
|
|
Trade and other
receivables |
|
41,749 |
77,158 |
Cash and cash
equivalents |
|
157,310 |
262,845 |
Current
assets |
|
199,059 |
340,003 |
|
|
|
|
Current
liabilities |
|
|
|
Trade and other
payables |
|
(93,699) |
(73,453) |
Current
liabilities |
|
(93,699) |
(73,453) |
|
|
|
|
Net Assets |
|
1,979,443 |
2,029,936 |
|
|
|
|
|
|
|
|
Equity |
|
|
|
Issued Share
Capital |
|
654,000 |
654,000 |
Share Premium |
|
2,350,630 |
2,350,630 |
Retained Earnings |
|
(1,025,187) |
(974,694) |
Total
Equity |
|
1,979,443 |
2,029,936 |
Statement of Changes in Equity
for the year ended 31 January
2021
|
Share
capital |
Share
premium |
Share
warrant reserve |
Retained earnings |
Total |
|
£ |
£ |
£ |
£ |
£ |
At 31 January
2019 |
654,000 |
2,350,630 |
14,095 |
(810,254) |
2,208,471 |
|
|
|
|
|
|
Total comprehensive
loss for the year |
- |
- |
- |
(178,535) |
(178,535) |
Warrants expired
during the period |
|
|
(14,095) |
14,095 |
- |
At 31 January
2020 |
654,000 |
2,350,630 |
- |
(974,694) |
2,029,936 |
|
|
|
|
|
|
Total comprehensive
loss for the year |
- |
- |
- |
(50,493) |
(50,493) |
At 31 January
2021 |
654,000 |
2,350,630 |
- |
(1,025,187) |
1,979,443 |
Statement of Cash Flows
for the year ended 31 January
2021
|
|
Year
ended |
Year
ended |
31-Jan |
31-Jan |
|
|
2021 |
2020 |
|
|
£ |
£ |
Cash flows from
operating activities |
|
|
|
Loss for the year
before tax |
|
(50,493) |
(178,535) |
Investment income |
|
(27,583) |
(37,797) |
Foreign currency
exchange gain/loss |
|
(6,103) |
29,947 |
(Increase)/decrease in
receivables |
|
35,409 |
(43,869) |
Increase in
payables |
|
20,245 |
5,964 |
Fair value revaluation
of Investment |
|
(100,000) |
- |
Net cash outflow
from operating activities |
|
(128,522) |
(224,290) |
|
|
|
|
Cash flows from
investing activities |
|
|
|
Investment income
received net |
|
27,583 |
37,797 |
Purchase of
investments |
|
(4,594) |
(81,526) |
Net
cash outflow from investing activities |
22,989 |
(43,729) |
|
|
|
|
Net
decrease in cash and cash equivalents during the year |
(105,533) |
(268,019) |
|
|
|
|
Cash at the beginning
of year |
|
262,844 |
530,863 |
|
|
|
|
Cash
and cash equivalents at the end of the year |
157,310 |
262,844 |
Notes
1. General information
Limitless Earth Plc is a company incorporated and domiciled in
the United Kingdom. The Company is
a public limited company, which is listed on the AIM market of the
London Stock Exchange. The address of the registered office is
Suite 2, Northside House, Mount Pleasant, Barnet, Hertfordshire, England, EN4 9EB.
The Investing Policy is to invest principally, but not
exclusively, in sectors where changing demographic factors are
important drivers of growth. The Company intends to focus initially
on projects located in Europe but
will also consider investments in other geographical regions. The
Company may become an active investor, acquire controlling stakes
or minority positions, in each case, as the Board considers
appropriate and commercial.
The financial statements are presented in Pounds Sterling, which
is the Company’s functional and presentational currency.
The summary above is an extract of the report and accounts to
31 January 2021, which should be read
in full. References to page numbers and notes are in relation
to the pagination and contents of the full report and accounts, a
copy of which is available from the Company’s website.
2. Summary of Significant
Accounting Policies
Basis of preparation
The financial statements have been prepared in accordance with
International accounting standards (IASs) in conformity with the
requirements of the Companies Act 2006. The financial statements
have also been prepared under the historical cost convention, as
modified by the revaluation of financial assets at fair value
through profit or loss.
The preparation of financial statements in conformity with IASs
requires the use of certain critical accounting estimates. It
also requires management to exercise its judgement in the process
of applying the Company’s accounting policies. The areas
involving a higher degree of judgement or complexity, or areas
where assumptions and estimates are significant to the financial
statements are disclosed later in these accounting policies.
Going Concern
At the reporting date the Company had cash resources of
£157,310. and the Directors have prepared cash forecasts that show
that, at the time of approving the financial statements, the
Company has adequate resources to continue in existence for the
foreseeable future. Thus, they continue to adopt the going
concern basis of accounting in preparing the financial
statements.
3. Financial Asset
Investments
|
2021
£ |
2020
£ |
On 1 February |
1,763,386 |
1,711,809 |
Cost of investment purchases |
4,594 |
81,526 |
Foreign currency exchange
gain/(loss) |
6,103 |
(29,948) |
Fair value revaluation |
100,000 |
- |
31 January – Investments at fair
value |
1,874,083 |
1,763,386 |
Categorised as: |
|
|
Level 3 – Unquoted investments |
1,874,083 |
1,763,386 |
|
1,874,083 |
1,763,386 |
The valuation model adopted by management is explained in Note
3, Critical accounting judgements and estimations and is applicable
to each of the investments listed below:
Chronix Biomedical Inc (“Chronix”)
On 8 October 2015 the Company made
an investment in Chronix of US$500,000 (approximately £329,511) in the series
I round of convertible preference stock (“Series I Stock”) at a
price of US$0.40 per share. On a
fully diluted basis, considering all classes of common and
preference stock in issue, at the date of investment, Limitless’
investment represented 0.72% of Chronix’s issued share capital and
values Chronix at approximately US$69
million.
On 20 September 2019, the company
announced that it made a further investment of $100,000 ( £81,526) in form of a promissory
note.
On 19th Match 2021, the company announced that Chronix had
entered into an agreement with Oncocyte Corporation Inc.
(“Oncocyte”), a listed US based molecular diagnostics company, for
its acquisition for cash, equity and a future revenue share
consideration.
On 20th April 2021 and
after the financial year, Chronix repaid $109,460.09 which comprises of the $100,000 promissory note interest.
V Nova International Ltd
(“V-Nova”)
On 18 December 2015, the Company
made a cash investment of £500,000 in V-Nova, a company that
specialises in Advanced Signal & Data Compression Solutions.
The investment was through the acquisition of £500,000 worth of
Convertible loan notes. On 4 April
2017, these notes were converted into 7,284,382 Series B1
Participating shares at a 20% discount to the preferential
valuation of V-Nova at the time, of £100 million.
On 30 October 2020, V-Nova raised
£16,810,410 on a series C1 funding round and the company settled
unconverted loan not holders with £8,556,144 cash. V Nova raised
further £5,661,027 in December 2020.
These C1 shares and the company’s B1 shares rank similarity and the
investment fair value uplift in note 12 is based on the increase in
the placing price. A fair value uplift of £100,000 was recognised
using the price per share in the October
2020 fund raise as a valuation.
Saxa Gres S.A (”Saxa”)
On 23 December 2015, the Company
invested €350,000 (approximately £258,830) in Saxa. As a
first round subscriber, Limitless has also been granted an option
to acquire 1.1655 per cent. of the equity in Saxa at nominal value
with the intention that, once the bonds have been repaid, Limitless
will be able to maintain an interest in Saxa of approximate value
to the bond investment.
On 21 March 2017, Limitless
announced that it had increased its investment in Saxa Gres by
acquiring a further 267 Notes for a value of €267,000. These Notes
were also accompanied by options to acquire shares in Saxa Gres, in
this case to acquire another 1.333% of its equity share capital
with each option having an exercise price of €1. In total,
Limitless has options to acquire approximately 2.5% of the equity
share capital of Saxa Gres at an exercise price of €1 per
share.
On 16 November 2017, the company
announced that it had made a further investment in Saxa Gres S.p.A.
of approximately EUR €75,000 in form of a loan . Saxa Gres
was raising funds, via an increase in its share capital, in order
to invest in a new production line, it required to meet a
significant increase in orders. Limitless participated alongside
two sizable credit funds in order to maintain its interest in Saxa
Gres.
On 19th January 2021, the company
announced that a recent investor in Saxagress, was A2A S.p.A., a €4
billion listed company, as a Saxa Gres shareholder (27.7%) and as a
relevant industrial partner which could help to expand and solidify
Saxa Gres’ successful business model.
At the request of Saxa Gres in order for it to gain better
access bank financing to further its investment plans, the Board of
LME, together with 96% of the existing 2023 bond holders, agreed to
exchange its 617 Saxa Grs bond notes with maturity in 2023 into a
similar amount of Saxa Gres notes of 7 per cent. with maturity in
2026.
Exogenesis
On 6 May 2016, the Company made an
investment in Exogenesis, a nanotechnology company which has
developed nanoscale surface modification technology to, inter
alia, improve the safety and efficacy of implantable medical
devices and is being used to develop next generation microscopy
tools for DNA analysis.
The Company invested US$300,000
(approximately £200,000) in the Exogenesis senior convertible notes
which accrued an 8 % annual interest (“Notes”). The Notes,
together with accrued interest, are convertible into Exogenesis
series B preferred stock at a price of US$0.382 per share or, at the option of
Limitless, into Exogenesis series C preferred stock at a 20 %
discount to the issue price at the time of the next
financing.
On 9 June 2017, the Company
extended the maturity date of the loan notes to 31 December 2017 from 30
June 2017 and lowered the conversion threshold amount to
$2,500,000. Upon the cash financing
being achieved and the maturity date being reached, the notes were
then converted into series B preferred stock at the agreed
price.
The table of investments sets out the fair value measurements
using the IFRS 13 fair value hierarchy. Categorisation within
the hierarchy has been determined on the basis of the lowest level
of input that is significant to the fair value measurement of the
relevant asset as follows:
Level 1 – valued using quoted prices in active markets for
identical assets.
Level 2 – valued by reference to valuation techniques using
observable inputs other than quoted prices included within Level
1.
Level 3 – valued by reference to valuation techniques using
inputs that are not based on observable market data.
The valuation techniques used by the Company are explained in
the accounting policy note, “Financial asset investments”.
LEVEL 3 FINANCIAL ASSETS
Reconciliation of Level 3 fair value measurement of financial
assets:
|
2021
£ |
2020
£ |
Brought forward |
1,763,386 |
1,711,809 |
Purchases |
4,594 |
81,526 |
Foreign currency
exchange gain /(loss) |
6,103 |
(29,948) |
Fair value
revaluation |
100,000 |
- |
Carried forward |
1,874,083 |
1,763,386 |
No unobservable inputs were used in the fair value measurement
for assets categorised in Level 3 of the fair value hierarchy. No
sensitivities have been included on the other investments, as their
fair value equates to cost.
4. Earnings Per Share
(a) Basic
Basic earnings per share is calculated by dividing the loss
attributable to equity holders of the Company by the weighted
average number of ordinary shares in issue during the period.
|
2021 |
2020 |
£ |
£ |
Loss from continuing
operations attributable to equity holders of the company |
(50,493) |
(178,535) |
Weighted average
number of ordinary shares in issue |
65,400,000 |
65,400,000 |
|
Pence |
Pence |
Basic earnings per
share from continuing operations |
(0.00077) |
(0.0027) |
(b) Diluted
Diluted earnings per share is calculated by adjusting the
weighted average number of ordinary shares outstanding to assume
conversion of all dilutive potential ordinary shares. There were no
potentially dilutive instruments outstanding at 31 January
2021.
5. Post Year End
Events
On 20th April 2021 and after the
financial year, Chronix repaid $109,460.09 which comprises of the $100,000 promissory note and interest.
On 29th July 2021, the Company
entered in to an agreement with an FCA regulated broker to dispose
30 Saxa Bonds ISIN: IT0005418436 (for a nominal value of €29,131.73
net of a 3.5% commission) and further 220 Bonds (for a nominal
value of €220,000 at the prevailing market conditions and
gross before a commission of 5%), in various tranches from October
to 31 December 2021, with an
undertaking that the further 220 Bonds will be purchased by the
broker and accounted for no later than 31
December 2021.